The US Food and Drug Administration (FDA) has approved Infilbray (venglustat) for the treatment of neurological manifestations of Gaucher disease type 3 (GD3) in adults and pediatric patients weighing at least 15 kg.

GD is a genetic lysosomal disordercaused by genetic changes in the GBA gene that lead to reduced levels of glucocerebrosidase that in turn results in the accumulation of toxic levels of glycosphingolipid in cells. Signs and symptoms vary widely among affected individuals and may include skeletal disorders, hepatosplenomegaly, liver malfunction, anemia, low platelet counts, bone problems, and neurological problems. There are three main forms of the disease: GD1, characterized by lack of central nervous system involvement; GD2, marked by rapid neurological decline and severe neurocognitive symptoms; and GD3, marked by slower and more variable progression and symptom severity.

Venglustat is a novel, oral glucosylceramide synthase inhibitor (GCSi) that acts across the blood-brain barrier, and inhibits abnormal glycosphingolipid accumulation present in GD.

The approval is largely based on data from the phase 3 LEAP2MONO clinical trial (NCT05222906) evaluating the safety and efficacy of venglustat in adults and pediatric patients aged 12 years and older with neurological manifestations of GD3 who previously achieved stabilization of their systemic manifestations with enzyme replacement therapy (ERT).

Venglustat demonstrated improvements in neurological manifestations causing cognitive deficits and difficulty with coordination and balance over the ERT imiglucerase, with a global test of multiple neurological endpoints showing statistically significant superiority.

The reported adverse reactions in the primary analysis period of the LEAP2MONO study among patients receiving venglustat versus imiglucerase were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.

Venglustat does not have a Black Box Waring, however,  the medication does carry Warnings and Precautions for suicidal ideation and behavior, lens opacification in pediatric patients, and embryofoetal toxicity.

For more information, visit https://www.news.sanofi.us/2026-11-18-Sanofis-Infilbray-approved-in-the-US-as-the-first-medicine-to-treat-neurological-manifestations-of-Type-3-Gaucher-disease

To learn more about Gaucher disease and other rare lysosomal storage disorders, visit https://checkrare.com/diseases/lysosomal-storage-disorders/